Post Covid-19 Infection Presenting as Rhino-Orbital Mycosis

Richa Garg¹ · Sandeep Bharangar² · Sunil Gupta³ · Samiksha Bhardwaj⁴

Received: 15 June 2021 / Accepted: 27 June 2021 / Published online: 14 July 2021
© Association of Otolaryngologists of India 2021

Abstract Rhino-orbital mycosis has been recently recognised as one of the sequelae in COVID-19 recovered patients. In India, detection of mucormycosis is declared as notifiable disease. In this article, the authors aim to describe the characteristics of patients presenting with post covid fungal infection which could be detected on 10% potassium hydroxide (KOH) wet mount and Giemsa stain put on crush biopsy smear. We describe 10 COVID-19 recovered patients admitted to ENT department of the hospital during second wave of COVID-19 infection. They presented with post covid fungal sinusitis and ophthalmic complications and planned for surgery. KOH mount and Giemsa stain were used for possible opinion and confirmed by culture. The observations were described in mean and percentages. All ten (100%) COVID-19 recovered patients were previously diagnosed with type 2 diabetes mellitus (DM) for 2–11 years. All 10 patients (100%) were given oral or intravenous corticosteroids for mean of 21 days (3 weeks—till presentation to ENT department). Simple procedures with 10% KOH mount and Giemsa stain could detect fungal hyphae in all the cases and could provide possible opinion in 9 of 10 (90%) cases for timely management of the patients. The authors hypothesize that

uncontrolled DM and prolonged use of corticosteroids may act as culprits of rhino-orbital mycosis in COVID-19 recovered patients. Simple and routine 10% KOH mount and Giemsa stain may provide early opinion of fungal hyphae to ensure quick management and survival of the patients.

Keywords Covid-19 · Diabetes-mellitus · Corticosteroids · Mucormycosis · KOH · Giemsa

Introduction

Coronavirus disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV2). The infection spreaded across the continents resulting in pandemic [1]. The first wave hit the patients more severely with comorbidities like diabetes mellitus (DM), heart problems, body mass index > 40 kg/m² and age > 60 years [2]. The second wave of COVID-19 is more severe and brought healthcare system to use plasma therapy, remdesivir injections, corticosteroids and oxygen cylinders [1]. The clinical manifestations of patients with COVID-19 infection are common in both waves: fever, cough, fatigue and shortness of breath [1]. The second wave has also come across features like headache, localised pain, nasal discharge, sinusitis, orbital cellulitis and diminution of vision due to rhino-orbital fungal infection occurring few weeks after recovery of COVID-19 patients [3–5]. Fungal infection mainly affects people on medication due to their reduced ability to fight environmental pathogens [3–6]. The detection of mucormycosis— an uncommon opportunistic invasive fungal infection is declared as notifiable disease under Epidemic Diseases Act 1897 on 19 May 2021 in India. Mucormycosis is caused by species of *Rhizopus*,

✉ Richa Garg
richag24@gmail.com

¹ Consultant Pathologist, Crest Hospital, Moradabad, Uttar Pradesh, India

² Consultant Otolaryngologist, Crest Hospital, Moradabad, Uttar Pradesh, India

³ Consultant Ophthalmologist, Sahu Rameshwar Saran Hospital and Research Centre, Moradabad, Uttar Pradesh, India

⁴ Consultant Radiologist, Crest Hospital, Moradabad, Uttar Pradesh, India

Mucor and *Absidia* [7]. It may be a terminal complication of uncontrolled diabetes. The incidence of mucormycosis has increased considerably as a result of widespread use of steroids, antibiotics and antimetabolites [4–7]. The infection starts in the upper respiratory tract or nose by inhalation of spores and may invade adjacent tissues like orbit, sinuses and brain [7]. Till date approximately 28,200 cases of mucormycosis have been recorded in India [8]. Warning signs of rhino-orbital fungal infection include sinusitis, blurred vision, redness of eye, blocked nose, local pain, blackish discoloration over bridge of nose and palate on clinical examination [3–5]. The other opportunistic fungal infections reported in COVID-19 patients are oropharyngeal candidiasis and respiratory tract aspergillosis [9]. The commonly used fungal stain is KOH as wet mount to demonstrate fungal hyphae on the nasopharyngeal swab [7]. The present article demonstrates the characteristics of COVID-19 recovered patients presenting with clinical features suspicious of rhino-orbital fungal infection and the use of routine KOH mount and Giemsa stain on crush biopsy smear for early detection and management.

Methods

The clinical details of 10 patients who were recovered from COVID-19 infection and admitted to ENT department in the hospital in month of May 2021 were noted down (Table, Fig. 1a). Imaging was done in each case as computed tomography (CT) or magnetic resonance imaging (Fig. 1b). Nasal endoscopy was done in all 10 cases (Fig. 1c). The cases with intracranial extension on imaging were referred to higher centre and not considered. Advanced endoscopic sinus surgery (AESS) was planned in all 10 cases after taking written consent. The operated specimen was labelled as nasal/paranasal mucosa and sent to lab in normal saline for fungal microscopy (Fig. 2a). Two crush smears were made from the blackish area of the specimen (Fig. 2b) and stained with 10% KOH and giemsa stains respectively (Fig. 2c-d). Microscopy was done first at 20X and then 40X. Broad, aseptate to sparsely septate, wide angled branching fungal hyphae were considered belonging to order mucorales and thin septate acute angled branching fungal hyphae were suggestive of aspergillus. [7], The rest of the biopsy specimen was outsourced for fungal culture. The observations and results are expressed in mean and percentages.

Observations

The clinical features of 10 patients are tabulated in table (Table 1). In the present article, 6 of 10 (60%) were male and 4 of 10 (40%) were females patients. The mean

age of the patients admitted was 53.3 (28–70 years). The predominant symptom was headache seen in 10 of 10 (100%) patients, diminution of vision was observed in 3 of 10 (30%) patients. Other complaints were cheek swelling, nasal obstruction, nasal discharge and localised pain (Fig. 1a). All 10 cases were not vaccinated. All patients were COVID-19 positive reported either by reverse transcriptase polymerase chain reaction (rtPCR) positive seen in 6 of 10 cases (60%) or antigen positive observed in 4 of 10 (40%) of patients. The mean number of days with patients presenting with rhino-orbital fungal infection was 24.6 days (range 22–28 days) from their COVID -19 positive status. Imaging as CT or MRI was done in all the cases which showed infective sinusitis in 7 of 10 cases (70%). The predominant risk factor was DM type –II seen in 10 of 10 cases (100%) present for a mean of 4.5 years (range 2–11 years). The mean random blood glucose level at presentation to ENT department was 299.4 mg/dl (range: 185–447 mg/dl). All patients (100%) were taking oral hypoglycemic drugs and 4 of 10 (40%) were using insulin also. All 10 patients (100%) were given oral corticosteroids as part of management of COVID-19 infection for mean of 24 days (range: 21 days- till presentation to ENT department). The administered doses were methylprednisolone (MP) 16 mg TDS or dexamethasone (DX) 8 mg BD with tapering doses over weeks. The oxygen saturation of the patients during COVID-19 positivity ranged from 90 to 99%. However, none of the patients required ventilator support or admission in ICU. 3 of 10 (30%) patients required 2 litre–8 litre external oxygen support through oxygen cylinders for 5–7 days. All 10 of 10 (100%) patients underwent nasal endoscopy and later were planned for AESS as treatment modality. In all the patients, the operative mucosal specimen was labelled and sent to pathology lab for fungal microscopy and culture. On microscopy with KOH mount and Giemsa stain, broad aseptate to sparsely septate fungal hyphae possibly belonging to order mucorales/mucormycosis were noted in 7 of 10 (70%) cases (Fig. 3a-b) and thin acute angled, branched septate fungal hyphae possibly belonging to family aspergillus observed in 2 of 10 (20%) cases (Fig. 3c-d). Predominantly thin septate and occasional broad sparsely septate fungal hyphae seen in 1 of 10 (10%) cases and was reported as possibly mixed infection (Fig. 3e). The reports could later be confirmed by fungal culture as 7 cases of mucormycosis (70%) and 3 aspergillus (30%). So, in 9 of 10 cases (90%), KOH mount and giemsa stain could provide opinion correlating with fungal culture. All the patients were given antibiotics and antihistaminics post surgery and advised for nasal douching. 3 of 7 patients 42.8% diagnosed with mucormycosis were given liposomal amphotericin B (5 mg/kg/day) and 1 of 3 patients (33.3%) diagnosed with aspergillosis was given oral posaconazole in a dose of 50

Fig. 1 **a** Patient presenting with nasal blockage, local pain and orbital swelling. **b** Nasal endoscopy showing pale mucosa with black necrotic eschar. **c** CT scan showing rhino-orbital mucosal thickening, edema and mass collection suggestive of infective etiology

mg TDS for 5 days at the time of resolution. The ophthalmoplegia regained back after AESS in all 3 of 3 (100%) of patients presenting with diminution of vision with better perception of light after 5–7 days of surgery. None of the deaths reported so far.

Discussion

Coronavirus disease is caused by SARS-CoV2 virus which has infected approximately 174 million people globally so far. According to WHO, India has reported 29,359,155 confirmed cases of COVID-19 infection with 367,081 deaths from 3 January 2020 to 12 June 2021 [10]. COVID-19 infection has hit India badly during the second wave. On May 7th 2021, India has recorded its ever highest 4.14 lakhs COVID-19 cases in a single day [10]. The most common symptoms of covid-19 remain fever, dry cough and fatigue. People above 60 years of age, with heart and lung problems, obese, diabetic are at higher risk of

becoming critically ill. People who have had COVID-19 infection whether hospitalized or not continue to experience fatigue, respiratory and neurological symptoms for some time [10].

The COVID-19 infection dysregulates CD4 + and CD8 + cells disturbing the innate immunity which increases the chances of secondary fungal and bacterial infections [11, 12]. In our article, all the 10 patients were COVID-19 positive (22–28 days) before detection of fungal infection. COVID-19 patients have more pro-inflammatory (IL-1, IL-2, IL-6, tumor necrosis factor- α) cytokine levels and less CD4 interferon-gamma expression which increases the risk of invasive fungal infection in them.

Mucormycosis and aspergillosis are important opportunistic systemic mycoses. Their spores are inhaled in immunocompromised states which germinate in nasal cavity, paranasal sinuses, lung orbit and brain which may lead to death [7, 12]. All our 10 patients were 2–11 years old diabetic. Diabetes is a state of immunosuppression.

Fig. 2 **a** Blackish to pinkish mucosal specimen. **b** smear preparation from blackish area of specimen. **c** Smear with 10% KOH wet mount. **d** Smear stained with Giemsa stain

Hyperglycemia in diabetic patients disrupts immune response and affects cellular immunity, causes defective phagocytosis, suppresses cytokine production and results in failure to attack microbes causing invasion by secondary fungal infections [13]. COVID-19 infection virus (SARS-Cov 2) itself causes hyperglycemia as the virus damages the pancreatic islets due to cytokine storm [10, 14]. So, the blood glucose levels increase significantly in already diabetic patients when infected with COVID-19. It is recommended by WHO to monitor blood glucose levels twice daily for 3–4 days in COVID-19 patients and to start insulin if pre-meal blood glucose level is ≥ 180 mg/dl or post-meal blood glucose ≥ 250 mg/dl to avoid uncontrolled hyperglycemia [10]. In our article, 7 of 10 cases were confirmed as mucormycosis and 3 of 10 cases as aspergillus. The authors noted that mucormycosis which was seen in 70% of cases had random blood sugar level more than 300 mg/dl at presentation while in 30% cases noted as aspergillus had blood sugar level less than 300 mg/dl. So, we may hypothesize that mucorales need

more sugar level for their growth. However, more research needs to be done for its support.

The second wave of COVID-19 infection caused extensive use of corticosteroids as a part of COVID-19 management either as hospital care or at home under online supervision. Glucocorticosteroids have anti-inflammatory and immunosuppressive effects.

Steroids antagonize IL-1, IL-6, TNF and microbicidal activities of activated macrophages [15].

Some studies have shown that prolonged use of corticosteroids to control cytokine storm contributed to more susceptibility to fungal infection due to their immunosuppressive behaviour [11, 12, 14, 15]. Steroids also affect glycemic status causing hyperglycemia. According to WHO, if COVID patient is initiated on steroids, blood glucose monitoring should be done as before breakfast, lunch and dinner and after dinner also [10]. In our article, all 10 of 10 patients have used high doses glucocorticosteroids (Table 1) at least for 3 weeks and 4 of 10 were taking steroids till they were presented to ENT department.

Table 1 Clinical details of ten Covid-19 recovered patients

S. No.	1	2	3	4	5
Patient's Age/sex	65 Y/ M	60Y/M	48Y/F	52Y/F	62Y/F
Clinical features	Headache, left facial pain, diminution of vision, orbital swelling × 2 weeks	Headache, fullness nose, pain, nasal obstruction × 15 days	Headache, pain left cheek, diminution of vision × 10 days	Headache, pain at left eye brow area × 14 days	Headache, left nasal discharge and deviation × 15 days
Vaccine taken (Yes/No)	No	No	No	No	No
Past Covid-19 / current status: Days (d)	+ rtPCR 25d back/— present	+ rtPCR 22d back/— present	+ Antigen 26d back /— present	+ Antigen 24d back/— present	+ rtPCR 28d back/— present
Imaging	CT- PNS & orbit: left paranasal sinusitis & medial orbital floor swelling	CT-PNS mucosal thickening, loose mass at ethmoidal sinus ?fungus	MRI- Frontal, ethmoid and maxillary sinusitis with infective etiology	CT- PNS: mucosal thickening with sinusitis Infective etiology	CT- PNS & orbit: left maxillary sinusitis & fluid collection in space of left orbit
Risk Factors: DM x years (random blood glucose at presentation)/other	DM type2 × 5 years (313 mg/dl)	DM type2 × 3 years (349 mg/dl), Hypertension	DM type2 × 4 years (192 mg/dl)	DM type2 × 11 years (338 mg/dl)	DM type2 × 2 years (185 mg/dl)
Oral hypoglycemic drugs	Yes	Yes + Insulin	Yes	Yes + Insulin	Yes
Steroids dosing (MP/ DX) & duration of weeks	Oral MP 16 mg BD × 2 weeks, 8 mg MP BD × 1 week	Iv DX 8 mg BD × 10d oral steroids × till presentation to ENT	Oral 16 mg MP TDS with tapering × till presentation	80 mg solu-medrol TDS with tapering × 2 week + oral MP till presentation	80 mg solu-medrol BD with tapering on oral steroids × 4weeks
Oxygen saturation during covid-19 infection	95–98% O2 saturation without any support	97–98% without external O2 support	96–98%, no external O2 support	90–95% on oxygen cylinder 5 days	92–95% on 2-3L oxygen for 6 days
ICU admission	No	No	No	No	No
Nasal endoscopy	Yes	Yes	Yes	Yes	Yes
On KOH wet mount/ Giemsa stain	Broad aseptate fungal hyphae +	Broad aseptate fungal hyphae +	Thin septate fungal hyphae +	Broad sparsely septate fungal hyphae +	Thin septate fungal hyphae +
Fungal culture report	Rhizopus oryzae: Mucormycosis	Rhizopus oryzae: Mucormycosis	Aspergillus flavus	Rhizopus microsporus: Mucormycosis	Aspergillus flavus
Treatment plan	AESS + nasal douching + antibiotics + antihistaminics	Same + Liposomal Amphotericin B 5 mg/kg/day	Same + Posaconazole 50 mg TDS × 5d	Same + liposomal Amphotericin B 5 mg/ kg/day	Same
Follow-up	Well -survived till date	Well survived till date	Well survived till date	Well survived till date	Well survived till date
S. No.	6	7	8	9	10
Patient's Age/sex	38Y/M	58Y/M	52Y/M	70Y/F	28Y/M
Clinical features	Headache, diminution of vision right eye × 12 days	Headache, red eye, fullness in nose × 15 days	Headache, right nose block, pain at nasal area × 10 days	Headache, right nasal discharge and deviated × 2 weeks	left Nasal block, headache, eyebrow pain × 10 days
Vaccine taken (Yes/ No)	No	No	No	No	No
Past Covid-19 / current status: Days (d)	+ Antigen 24d back/— now	+ Antigen 26d back/— present	+ rtPCR 24d back/— present	+ rtPCR 25d back/— present	+ rtPCR 24d back/— present

Table 1 continued

S. No.	6	7	8	9	10
Imaging	CT-PNS & orbit: fungal/allergic sinusitis and orbital cellulitis	CT- mucosal thickening, mass ?fungal	CT-maxillary and ethmoidal sinusitis s/o infective etiology	MRI: hyperintense signals in rt frontal & maxillary & hypointense at ethmoid sinuses	CT-s/o Fungal /allergic sinusitis
Risk Factors:DM x years (random blood glucose at presentation)/other Oral hypoglycemic drugs	DM type2 × 4 years (447 mg/dl) yes + insulin	DM type2 × 3 years (220 mg/dl), Hypertension yes	DM type2 × 4 years (300 mg/dl) yes	DM type2 × 7 years (350 mg/dl) Yes + insulin	DM type2 × 2 years 300 mg/dl) Yes
Steroids dosing (MP/ DX) & duration of weeks	Oral 8 mg MP TDS × 3 weeks	16 mg MP TDS with tapering × 25 days	80 mg solu-medrol TDS with tapering × till present-ation	Oral 16 mg Mp TDS with tapering × 24 days	Oral MP 16 mg TDS × 2week with taper 8 mg TDS 1 week
Oxygen saturation during covid-19 infection	98–99% without external O2 support	96–99% without external O2 support	92–94% on 6–8 L oxygen for 7 days	96–98% without external O2 support	97–98% Without external oxygen
ICU admission	No	No	No	No	No
Nasal endo-scopy	Yes	Yes	Yes	Yes	Yes
On KOH wet mount/ Giemsa stain	Broad aseptate fungal hyphae +	Predominantly thin, mixed fungal hyphae +	Broad aseptate fungal hyphae +	Broad aseptate fungal hyphae +	Broad sparsely septate hyphae +
Fungal culture report	Rhizopus oryzae: Mucormycosis	Aspergillus oryzae	Rhizopus oryzae: Mucormycosis	Rhizopus oryzae: Mucormycosis	Rhizopus microsporus: mucormycosis
Treatment plan	Same	Same	Same + liposomal Amphotericin B 5 mg/ kg/day	Same	Same
Follow-up	Well survived till date	Well survived till date	Well survived till date	Well survived till date	Well Survived till date

Fig. 3 **a** Smear showing broad, wide angled aseptate fungal hyphae (thick arrow) possibly belonging to Mucormycosis (10% KOH 40X). **b** Smear showing broad, wide angled aseptate fungal hyphae (thick arrow) possibly belonging to Mucormycosis. Background shows inflammatory cells and necrosis (Giemsa 40X). **c** Smear showing thin, acute angled septate fungal hyphae (thin arrow) possibly belonging to aspergillus (10% KOH 40X). **d** Smear showing thin, acute angled

septate fungal hyphae (thin arrow) possibly belonging to aspergillus. Background contains few inflammatory cells (Giemsa 40X). **e** Smear showing predominant thin septate fungal hyphae (thin arrow) with occasional sparsely broad (thick arrow) fungal hyphae (10% KOH 40X)

This may further suppressed their immunity causing opportunistic fungal infection. The prevailing guidelines in India recommends intravenous methyl prednisolone 0.5–1 mg/kg/day or dexamethasone 0.1–0.2 mg/kg/day for moderate COVID-19 cases and 1–2 mg/kg/day or 0.2–0.4 mg/kg/day dexamethasone for severe cases for total of 5–10 days and doesn't recommend steroids for mild cases with SpO₂ > 94% at room temperature [16].

In the present article, the authors hypothesize that the trinity of COVID-19 infection, uncontrolled diabetic status and prolonged use of corticosteroids may act as cofactor for each-other causing vicious cycle for suppression of immunity allowing secondary fungal infection. In our article, the predominant symptoms were headache, nasal blockage, pain at local area, diminution of vision after few days of COVID-19 infection recovery. These features may

be taken as initial warning symptoms in COVID-19 recovered patients for early suspicion of secondary fungal infection. Only 3 of 10 patients were given amphotericin B and 1 of 10 patients was given posaconazole. So, we hypothesize that post-surgical antifungals are not necessarily required till the tissue infection is restricted below skull bone. All the patients survived till date without any further complication.

The simple routine 10% KOH mount and Giemsa stain on crush biopsy smear may help for early diagnosis of fungal infection and to report the possible type of fungus for early management. Bala K et al showed in their study the utility of KOH wet mount for detection of mucormycosis [17]. The detection of fungal elements on Giemsa stain is rarely studied [18]. However, in cases where KOH mount may not help to visualize the type of fungal hyphae

clearly due to absence of colored staining, Giemsa stain may provide more light on type of fungal hyphae to differentiate non-septate from septate hyphae, to know mixed fungal and/or bacterial infection and to highlight the background.

Conclusion

Our study may be limited by short follow up duration but the authors primary aim was to report the characteristics of COVID-19 recovered patients who presented with rhino-orbital mycoses. Patients should be made aware of strict glycemic control and limited use of corticosteroids. Patients should seek immediate medical attention if develops headache, pain, facial swelling, diminution of vision so that timely medical action may be taken for ensuring survival. Surgical debridement of necrotic tissue is cornerstone of treatment which also provides sample for immediate fungal microscopy by KOH wet mount and Giemsa stain to provide quick possible diagnosis for timely management of the patients.

Funding There were no sources of funding (institutional, private and corporate financial support) for the work reported in this paper.

Declaration

Conflict of interest There was no conflict of interest either in designing and accomplishment of this study.

Consent for Publication The material has not been previously published or submitted elsewhere for publication.

Ethical Approval This manuscript has been read and approved by all the authors which represent our honest report of hard working.

Informed Consent Authors confirm that the statements of written informed consent from legally authorized representatives/parents/guardians are available.

References

- Gorthi RS, Kamel G, Dhindsa S et al (2021) AACE Clinical Case Rep 7:6–92
- Petrilli CM, Jones SA, Yang J, et al. 1966. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *BMJ*. 2020; 369(8249):m
- Maini A, Tomar G, Khanna, et al . Sino-orbital mucormycosis in a COVID-19 patient: A case report. *Int J Surg Case Rep* 82 (2021) 105957
- Dallalzadeh LO, Ozzello DJ, Liu CY, Kikkawa DO, Korn BS. 2021. Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. *Orbit*. Mar 23:1–4. <https://doi.org/10.1080/01676830.2021.1903044>. Epub ahead of print. PMID: 33752571
- Sen M, Lahane S, Lahane TP et al (2021) Mucor in a viral land: a tale of two pathogens. *Indian J Ophthalmol* 69(2):244–252
- These states have declared 'black fungus' a notifiable disease. Available from <https://www.hindustantimes.com> › india-news › these-st. Accessed on 9 June 2021
- Paniker C, Editor. Ananthanarayan and Paniker's Textbook of microbiology. Orient Longman Publisher. 2006; p. 610–620
- Over 28,200 'black fungus' cases recorded In India. Available from <https://www.aa.com.tr> › asia-pacific › over-28–200-blac. Accessed on 9 June 2021
- Salehi M, Ahmadi K, Badali H, Khodavaisy S. 2020. Opportunistic fungal infections in the epidemic area of COVID-19: A clinical and diagnostic perspective from Iran *Mycopathologia*; 185:607–11
- Information about COVID-19 - WHO Official Information - who.int
- Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H (2020) Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. *J Clin Invest* 130:2620–2629
- Moorthy A, Gaikwad R, Krishna S, Hegde R, Tripathi KK, Kale PG, Rao PS, Haldipur D, Bonanthaya K. 2021. SARS-CoV-2, Uncontrolled Diabetes and Corticosteroids-An Unholy Trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. *J Maxillofac Oral Surg*. Mar 6:1–8. <https://doi.org/10.1007/s12663-021-01532-1>. Epub ahead of print. PMID: 33716414
- Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R (2020) Type 2 diabetes and its impact on the immune system. *Curr Diabetes Rev* 16(5):442–449
- Liu, Yan MM^{a,b}; Yang, Yan MM^{a,b}; Chen, Yalin MM^{a,b}; Zhou, Linyue MD^{a,b}; Xiong, Qian MM^{a,b}; Xie, Chunguang MD^{a,*}. 2020. The relationship between hyperglycemia and the infection of COVID-19 in diabetic patients. *Medicine*. 99(36) p e21806
- Coutinho AE, Chapman KE. 2011. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. *Mol Cell Endocrinol*. 335 (1):2–13
- National clinical management protocol covid-19. Available from <https://www.mohfw.gov.in> › pdf › UpdatedDetail. Accessed on 12 June 2021
- Bala K, Chander J, Handa U et al (2015) A prospective study of mucormycosis in north India: Experience from a tertiary care hospital. *Medical Mycology* 53(3):248–257
- Zhang W, Yang H, Jiang L et al (1961) Techniques in the microscopic evaluation of corneal scrapings for diagnosis of fungal keratitis use of potassium hydroxide, giemsa and calcofluor white staining. *J Int Med Res* 2010(38):1961–1967

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.